Literature DB >> 21177526

Prevalence estimates for latent neurodegenerative disease.

Thomas J Montine1.   

Abstract

Diseases that commonly cause dementia in the general population are Alzheimer's disease, microvascular brain injury, and Lewy body disease. Each of these is a chronic disease with latent, prodromal, and dementia stages. Here I present outcomes from validated neuropathologic assessments and cerebrospinal fluid biomarkers to estimate the prevalence of the latent stage of diseases that commonly contribute to the dementia syndrome. The latent stage of diseases that commonly cause dementia is highly prevalent in the adult population, highlighting the need for prevention strategies and longitudinal studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177526      PMCID: PMC3062523          DOI: 10.1177/0192623310391481

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  9 in total

1.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

2.  Pathological correlates of dementia in a longitudinal, population-based sample of aging.

Authors:  Joshua A Sonnen; Eric B Larson; Paul K Crane; Sebastien Haneuse; Ge Li; Gerald D Schellenberg; Suzanne Craft; James B Leverenz; Thomas J Montine
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

3.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

4.  Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.

Authors:  Erik Stomrud; Oskar Hansson; Henrik Zetterberg; Kaj Blennow; Lennart Minthon; Elisabet Londos
Journal:  Arch Neurol       Date:  2010-02

5.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

Authors:  Geert De Meyer; Fred Shapiro; Hugo Vanderstichele; Eugeen Vanmechelen; Sebastiaan Engelborghs; Peter Paul De Deyn; Els Coart; Oskar Hansson; Lennart Minthon; Henrik Zetterberg; Kaj Blennow; Leslie Shaw; John Q Trojanowski
Journal:  Arch Neurol       Date:  2010-08

Review 6.  Mild cognitive impairment: an overview.

Authors:  Ronald C Petersen; Selamawit Negash
Journal:  CNS Spectr       Date:  2008-01       Impact factor: 3.790

Review 7.  Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia.

Authors:  Joshua A Sonnen; Kathleen S Montine; Joseph F Quinn; John C S Breitner; Thomas J Montine
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Survival after initial diagnosis of Alzheimer disease.

Authors:  Eric B Larson; Marie-Florence Shadlen; Li Wang; Wayne C McCormick; James D Bowen; Linda Teri; Walter A Kukull
Journal:  Ann Intern Med       Date:  2004-04-06       Impact factor: 25.391

9.  CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

Authors:  G Li; I Sokal; J F Quinn; J B Leverenz; M Brodey; G D Schellenberg; J A Kaye; M A Raskind; J Zhang; E R Peskind; T J Montine
Journal:  Neurology       Date:  2007-08-14       Impact factor: 9.910

  9 in total
  5 in total

Review 1.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

2.  Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer's disease from bioptic olfactory mucosa.

Authors:  Hannah Pellkofer; Friedrich Ihler; Bernhard G Weiss; Janina Trothe; Harindranath Kadavath; Monika Chongtham; Marcel Kunadt; Dietmar Riedel; Finn Lornsen; Petra Wilken; Claudia Bartels; Sina Hirschel; Sebastian G Russo; Elke Stransky; Lutz Trojan; Boris Schmidt; Eckhardt Mandelkow; Markus Zweckstetter; Martin Canis; Anja Schneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-12       Impact factor: 5.270

3.  Revising the Resistiveness to Care Scale.

Authors:  Rita A Jablonski-Jaudon; Vicki Winstead; Corteza Jones-Townsend; Andres Azuero; Ellen Mahoney; Ann M Kolanowski
Journal:  J Nurs Meas       Date:  2016

Review 4.  The evolution of preclinical Alzheimer's disease: implications for prevention trials.

Authors:  Reisa Sperling; Elizabeth Mormino; Keith Johnson
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

5.  Pathophysiology and Therapeutic Perspectives of Oxidative Stress and Neurodegenerative Diseases: A Narrative Review.

Authors:  Martina Rekatsina; Antonella Paladini; Alba Piroli; Panagiotis Zis; Joseph V Pergolizzi; Giustino Varrassi
Journal:  Adv Ther       Date:  2019-11-28       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.